Skelton Laurence Matthew 4

What Happened

• Laurence Matthew Skelton, Chief Commercial Officer of Vera Therapeutics (VERA), received equity awards on 2026-02-04 totaling 60,000 shares: 20,000 restricted stock units (RSUs) and rights to 40,000 derivative shares (stock option/award). Both grants show an acquisition price of $0, so no cash was paid by the insider. These are awards (transaction code A), not open-market purchases or sales.

Key Details

• Transaction date: 2026-02-04. Filing date (Form 4): 2026-02-06 (timely filing).
• Price: $0.00 per share for both the 20,000 RSUs and the 40,000 derivative award (total reported value = $0 on grant).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote F1 (RSUs): 20,000 RSUs vest 25% each year on Feb 20 of 2027, 2028, 2029 and 2030, subject to continued service.
• Footnote F2 (derivative): 40,000-share award vests 1/48th on March 4, 2026 and then monthly 1/48th thereafter, subject to continued service (standard time-based vesting).
• Transaction type: Award/grant (A). No sale, purchase, or immediate exercise/sale noted.

Context

• RSUs represent a promise to deliver shares on vesting; the derivative award is a time-vesting equity right (likely options) that vests monthly. Neither transaction provides immediate liquidity and both are typical components of executive compensation programs. The filing does not indicate any sale or cashless exercise tied to these awards.